The clinical meaning of functional outcome scores in children with juvenile arthritis

H Dempster1, M Porepa, N Young

  • 1University of Toronto, Ontario, Canada.

Arthritis and Rheumatism
|August 18, 2001
PubMed

Insights

A minimal clinically important improvement for the Childhood Health Assessment Questionnaire (CHAQ) in pediatric arthritis is a score reduction of 0.13. This finding aids clinicians and researchers in setting treatment goals for children with arthritis.

Area of Science:

  • Pediatric Rheumatology
  • Clinical Outcomes Measurement

Background:

  • The Childhood Health Assessment Questionnaire (CHAQ) is a standard functional measure for childhood arthritis.
  • CHAQ scores range from 0 (no disability) to 3 (severe disability).

Purpose of the Study:

  • To establish CHAQ score cutoffs for disability levels (none, mild, moderate, severe).
  • To determine the minimal clinically important change (MCIC) in CHAQ scores.
  • To compare parent-reported and self-reported MCIC in older children.

Main Methods:

  • 136 parents of children with arthritis completed the CHAQ assessing current status, slight improvement, and slight worsening.
  • Parents also used a subjective disability scale.
  • Children aged 10+ completed the CHAQ independently.

Main Results:

  • Most pediatric patients had no, mild, or moderate disability.
  • Median CHAQ scores for no, mild, mild-to-moderate, and moderate disability were 0, 0.13, 0.63, and 1.75, respectively.
  • MCIC for improvement was 0.13; for deterioration, it was 0.75. Self-assessments showed no significant differences.

Conclusions:

  • Clinicians and researchers should target a minimum CHAQ score improvement of 0.13 for pediatric arthritis patients.
  • The identified cutoffs and MCIC provide valuable benchmarks for functional status assessment.
Abstract

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...